(Reuters) – Lawyers for Bayer AG and consumers suing the company over allegations that its Roundup herbicide caused cancer told a judge on Thursday that they continue to solve thousands of cases, improving the prospect of $ 11 billion settle the disputes.  The hearing was a contrast to the disputed tone among the parties last month that the framework agreement could be resolved. the next set of cases scheduled for trial to be resolved soon.
USA District Judge Vince Chhabria in San Francisco stayed in litigation until November 2 and asked the parties for a status update at that time.
The parties have binding business to settle approximately 45,000 of the 125,000 claims received and rejected, according to lawyers involved.
Bayer, which acquired Roundup with its $ 63 billion acquisition of Monsanto in 201
Bayer shares closed 1% on Thursday at 54.41 euros ($ 63.51). The shares have fallen from a maximum of around 73 euros since the settlement announcement in June.
Judge Chhabria questioned the fairness of the phase-out plan, which suggested using an independent scientific panel to assess whether glyphosate-based herbicides caused Roundup cancer.
Days later, Bayer said it would revise that part of the proposal.
Bayer has said that Roundup is safe and important for farmers who use the herbicide in combination with the company's genetically modified seeds.
In 2015, the World Health Organization's cancer research arm determined that the herbicide was a "likely carcinogen." The United States and European regulators have ruled that glyphosate is not carcinogenic. Catalog